statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Carlsbad,CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), ( Palisade , Palisade Bio or the Company ), a biopharmaceutical company focused on developing and...

Palisade Bio Announces 1-for-15 Reverse Stock Split

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Palisade Bio files to sell 3.63M shares of common stock for holders

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA Research Report) and Palisade Bio...

Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)

Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end Formation of Clinical...

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Carlsbad,CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ( Palisade or the Company ), a biopharmaceutical company focused on developing novel therapeutics for...

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Palisade Bio (PALI) has released an update. Dive into the latest buzz from the financial world as a renowned company unveils a corporate update tha...

Palisade Bio's Corporate Shake-Up Sparks Investor Interest

Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision Advancement of PALI-2108 for the treatment of moderate-to-severe...

Palisade Bio Provides Corporate Update and Reiterates Guidance

Carlsbad,CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ( Palisade or the Company ), a biopharmaceutical company focused on developing novel therapeutics for...

Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

Palisade Bio, Inc.

 Bruce Sands MD, MS

 Palisade Bio, Inc.

 Florian Rieder, MD

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School...

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Palisade Bio exercises previously issued warrants fo $2.5M

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Volume	14,625.00
52-Wk High	$36.60
52-Wk Low	$3.82

PALI Palisade Bio Inc

About

Feed

News

Fundamentals